Adolor Corporation

NDA submission for Entereg (alvimopan) completed

Published in Food and Drug Law Weekly, July 30th, 2004

Adolor Corporation (ADLR) and GlaxoSmithKline (GSK) announced that Adolor has submitted the complete New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Entereg (alvimopan) capsules.

Adolor is seeking marketing approval of Entereg for the management of postoperative ileus (POI) by accelerating time to recovery of gastrointestinal (G.I.) function following abdominal or pelvic surgeries. POI is a temporary impairment of G.I. function that can occur following many types of surgery. GlaxoSmithKline and Adolor are collaborating on the worldwide development and commercialization of Entereg.

"One of our key targets for 2004 was to...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Food and Drug Law Weekly

Source: Food and Drug Law Weekly (2004-07-30)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry